Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia

• Autori principali: Megumi Kikuya (Autore), Kenta Furuichi (Autore), Takuya Hirao (Autore), Satoshi Endo (Autore), Naoki Toyooka (Autore), Kousei Ito (Autore), Shigeki Aoki (Autore)
• Natura: Libro
• Pubblicazione: Elsevier, 2021-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Tyrosine kinase inhibitors (TKIs) are widely utilized in clinical practice to treat carcinomas, but secondary tumor resistance during chronic treatment can be problematic. AKR1B1 and AKR1B10 of the aldo-keto reductase (AKR) superfamily are highly expressed in cancer cells and are believed to be invo...